Format

Send to

Choose Destination
J Am Acad Dermatol. 2014 Jun;70(6):1045-9. doi: 10.1016/j.jaad.2014.01.905. Epub 2014 Mar 20.

Atenolol versus propranolol for the treatment of infantile hemangiomas: a randomized controlled study.

Author information

1
Department of Dermatology, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile. Electronic address: alvaroabarzuaaraya@gmail.com.
2
Department of Dermatology, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
3
Department of Pediatric Cardiology, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.

Abstract

BACKGROUND:

Infantile hemangiomas have a dramatic response to propranolol, a nonselective beta-blocker. However, this treatment is not risk-free and many patients are excluded because of respiratory comorbidities. Atenolol is a cardioselective beta-blocker that may have fewer adverse events.

OBJECTIVE:

We sought to evaluate the effectiveness of atenolol against propranolol in a noninferiority trial.

METHODS:

In all, 23 patients met the inclusion criteria and were randomized to receive either atenolol or propranolol. Thirteen patients were treated with atenolol and 10 with propranolol. Follow-up was made at baseline, 2 weeks, 4 weeks, and then monthly for 6 months.

RESULTS:

Patients treated with atenolol had a complete response of 53.8% and 60% with propranolol, respectively. These results were nonsignificant (P = .68). Relevant adverse events were not reported.

LIMITATIONS:

The reduced number of patients could have influenced our results.

CONCLUSION:

Atenolol appears to be as effective as propranolol. We did not find significant differences between these results or any adverse events.

KEYWORDS:

atenolol; beta-blockers; hemangiomas; propranolol; randomized; treatment; trial

PMID:
24656727
DOI:
10.1016/j.jaad.2014.01.905
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center